James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Chesapeake Energy Corporation (CHK), Freeport-McMoRan Inc (FCX) and J M Smucker Co (SJM) Are 3 of Today’s Worst Stocks

Chesapeake Energy (CHK), J M Smucker (SJM) and Freeport-McMoRan (FCX) couldn't win for losing on Tuesday. Here's what you need to know.

Why Alphabet Inc Is the Best Home for Twitter (GOOGL)

Don't sleep on Alphabet (GOOGL). Disney and Microsoft have wiggled their way into the Twitter race, but Alphabet has the pole position.

Twitter Inc Is Still Just a Coin Toss (TWTR)

Twitter stock (TWTR) dished out big gains on Friday, but there's no assurance a deal will ever actually get done at a price everyone can live with.

Why Would Walt Disney Co Even WANT Twitter Inc? (DIS)

Twitter stock edges even higher now that Walt Disney (DIS) is reportedly interested in acquiring the struggling microblogging company.

GW Pharmaceuticals PLC- ADR Is a First-Rate Marijuana Stock (GWPH)

GW Pharmaceuticals (GWPH) brings credibility to a movement that would otherwise have none of its own. GWPH stock belongs on your watch list.